Thinking about today's trading pattern, I think we are seeing the beginnings of a slow market realisation that A2M's product lines are unique.
That is, with more companies establishing a small footprint in the Infant Formula market (ie. FNP), A2M's products will continue to have a niche position thanks to the A2 protein.
I think this advantage is far more compelling that Bellamy's organic range. I would think the same of the Blackmores / Bega product too.
Or perhaps I'm just stating the bleeding obvious here. But I think that's what I am seeing in the market behaviour. Just a theory.
Baron
A2M listing on ASX 300, page-27
-
- There are more pages in this discussion • 219 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add A2M (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$7.02 |
Change
0.170(2.48%) |
Mkt cap ! $5.075B | |||
| Open | High | Low | Value | Volume |
| $6.86 | $7.03 | $6.81 | $16.52M | 2.369M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10280 | $7.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $7.02 | 17972 | 4 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| A2M (ASX) Chart |